Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Patients at Increased Risk for the Development of Ventilator-associated Pneumonia in the Intensive Care Unit
Overview
- Phase
- Not Applicable
- Intervention
- microbiological characterization
- Conditions
- Biofilm Formation
- Sponsor
- Centre Hospitalier Universitaire Dijon
- Enrollment
- 61
- Locations
- 1
- Primary Endpoint
- Development of Ventilator-associated pneumonia (VAP)
- Status
- Completed
- Last Updated
- 2 months ago
Overview
Brief Summary
Ventilator-associated pneumonia (VAP) remains the most frequent healthcare-associated infection (HAI) in the intensive care unit (ICU) and one of the most critical risk factors associated with both significant morbidity as well as mortality. Although VAP treatment relies on early and appropriate antimicrobial therapy, several preventive measures have been described in the literature in order to limit its incidence and clinical impact in the ICU. Among these, preventing biofilm formation on the inner surface of the endotracheal tube appears to hold promise. Yet there is a lack of clinical relevant data documenting a causal relation between biofilm formation and VAP. Designed to overcome this critical limitation, the BIOPAVIR study intends to provide a better structural and microbiological characterization of endotracheal tube biofilm in critically ill patients at increased risk for the development of VAP in ICU during COVID-19 pandemic.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patient \> 18 years of age with mechanical ventilation for \>2 calendar days
Exclusion Criteria
- •inability to collect or dispatch the endotracheal tube for proper characterization within 24 hours post-extubation
Arms & Interventions
BIOPAVIR Cohort
Critically ill patient \> 18 years of age with mechanical ventilation for \>2 calendar days, at increased risk for the development of Ventilator-Associated Pneumonia in the Intensive Care Unit during COVID-19 pandemic.
Intervention: microbiological characterization
Outcomes
Primary Outcomes
Development of Ventilator-associated pneumonia (VAP)
Time Frame: Immediately after extubation of the patient
Provide a better understanding of the correlation between structural and microbiological characterization of endotracheal tube biofilm in critically ill patients and increased risk for the development of VAP in ICU during COVID-19 pandemic.
Secondary Outcomes
- Development of other VAP, healthcare-associated infection (HAI) or mortality(Immediately after extubation of the patient)